Navigation Links
Lupus Nephritis-Pipeline Insights, 2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Lupus Nephritis-Pipeline Insights, 2014

DelveInsight's," Lupus Nephritis-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Lupus Nephritis. This report provides information on the therapeutic development based on the Lupus Nephritis dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

- The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Lupus Nephritis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Lupus Nephritis and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Lupus Nephritis
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Lupus Nephritis Overview
- Lupus Nephritis Pipeline Therapeutics
- Lupus Nephritis Therapeutics under Development by Companies

- Lupus Nephritis Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Lupus Nephritis Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Lupus Nephritis Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Lupus Nephritis Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Lupus Nephritis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Lupus Nephritis – Discontinued Products
- Lupus Nephritis – Dormant Products
- Companies Involved in Therapeutics Development for Lupus Nephritis
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Lupus Nephritis, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Lupus Nephritis Assessment by Monotherapy Products
- Lupus Nephritis Assessment by Combination Products
- Lupus Nephritis Assessment by Route of Administration
- Lupus Nephritis Assessment by Stage and Route of Administration
- Lupus Nephritis Assessment by Molecule Type
- Lupus Nephritis Assessment by Stage and Molecule Type
- Lupus Nephritis Therapeutics – Discontinued Products
- Lupus Nephritis Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Lupus Nephritis, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Lupus Nephritis Assessment by Monotherapy Products
- Lupus Nephritis Assessment by Combination Products
- Lupus Nephritis Assessment by Route of Administration
- Lupus Nephritis Assessment by Stage and Route of Administration
- Lupus Nephritis Assessment by Molecule Type
- Lupus Nephritis Assessment by Stage and Molecule Type

To order this report: Lupus Nephritis-Pipeline Insights, 2014

Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. The Systemic Lupus Erythematosus Market Will Grow Dramatically Over the Next Decade, Increasing from Approximately $900 Million in 2012 to $4 Billion in 2022
2. New ALR-LRI Collaboration to Accelerate New Treatments for Lupus
3. Rheumatologists in the EU5 Give the Highest Satisfaction and Performance Ratings to Rituxan and Benlysta for the Treatment of Systemic Lupus Erythematosus (SLE)
4. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
5. Lupus Foundation of Florida Applauds Support for Biosimilars Legislation
6. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
7. Two Of The Nations Top Specialists In Lupus, Drs. Swamy Venuturupalli & Daniel Wallace, Join In Expanding Research On Auto-Immune Diseases
8. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
9. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
(Date:10/9/2015)... REDWOOD CITY, Calif. , Oct. 9, 2015 ... a presentation will be made at the annual European Society ... th to October 14 th , 2015 at the ...  The annual EuSEM is the largest meeting of emergency medicine ... and 90 countries represented. Data from the previously ...
(Date:10/9/2015)... Oct. 9, 2015 Ansun BioPharma announced a ... of America ) regarding the compassionate use of DAS181 ... a respirator who was co-infected with influenza and parainfluenza ... of therapy, O 2 requirement was reduced and ... able to go off the respirator on day 5. ...
(Date:10/9/2015)... , Schweiz, October 9, 2015 Der ... Dr.   Yutaka Kondo und Dr.   Junko Takita ...   2015 " geht an Dr.   Yutaka ... Der " JCA-Mauvernay Award   2015 ... Dr.   Junko Takita    ™ , das ...
Breaking Medicine Technology:
... Nov. 9, 2011 BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX® in the U.S. ... Tom Wegman, will present at the upcoming Lazard Capital ... Wednesday, November 16, 2011 in New York, NY.   ...
... 9, 2011 NeuroDerm , Ltd. ... and pharmacokinetic trial of ND0611, administered as an adjunct ... or Stalevo ® , in patients with advanced Parkinson,s ... sub-cutaneously via a dermal patch to increase the bioavailability ...
Cached Medicine Technology:
(Date:10/9/2015)... Orleans, LA (PRWEB) , ... October 09, 2015 ... ... with offices serving New Orleans and the surrounding communities, is initiating a combined ... and medical care for unwanted animals in southern Louisiana. , Animal Rescue ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the ... walks of life to save money on the high cost of their prescription ... per medication, individuals and families can receive their medications delivered direct from over ...
(Date:10/9/2015)... Salt Lake City, UT (PRWEB) , ... October 09, 2015 , ... ... 12-17, observes Mental Illness Awareness Week. For many teenagers facing mental illness, the stigma ... the help they need. , ViewPoint Center understands the importance of supporting teens ...
(Date:10/9/2015)... ... 09, 2015 , ... Ryan Fox, the founder and CEO ... Colorado, says the latest figures on the state’s sales of legalized marijuana acknowledge ... industry. , Last month, according to the website , Colorado's ...
(Date:10/9/2015)... ... October 09, 2015 , ... Amada Senior ... opened its newest office in Maryland – its Bethesda location. Amada ... as a project management technology consultant to many of the largest construction firms ...
Breaking Medicine News(10 mins):
... Salamon HealthDay Reporter , WEDNESDAY, Feb. 2 ... process to create ready-made, easily stored blood vessels that ... or kidney dialysis. Using donor tissue cultured on ... five years engineering the "off-the-shelf" blood vessels, which cannot ...
... , WEDNESDAY, Feb. 2 (HealthDay News) -- The huge winter ... some sections of the United States could also cause a ... while shoveling or playing in the snow, the American Academy ... of bending and heavy lifting, particularly in wet, heavy snow. ...
... doses of an inexpensive, FDA-approved hypertension medication may ... treatment. In a report in the early ... of Sciences , Massachusetts General Hospital (MGH) investigators ... by modifying the network of collagen fibers that ...
... Serious Adverse Events Consortium (iSAEC) announced today a ... to enroll subjects in research to identify genetic ... a range of serious drug-related adverse events (SAEs). ... developing SAE research cohorts, an essential component of ...
... to be more effective, Funding will support future clinical trials ... A new study led by researchers at Rhode Island ... and EpiVax. Inc, a privately owned vaccine development company in ... colonization of Helicobacter pylori ( H. pylori ) ...
... treatment, the health care services can, on the one hand, ... the other hand, find appropriate ways to care for those ... The cancer care services in Lund, Sweden, set up ... early as 1987. Twenty years later, in 2007, Lund organised ...
Cached Medicine News:
... has the highest g-force ever. But optimal ... force. Optima MAX combines maximum force, capacity, ... performance that's worlds apart from any other ... and enhanced efficiency, Optima takes productivity to ...
... of generating 694,000 x g ... rpm, Beckman Coulter's Optima L-90K ... more separations in less time. ... with a broad range of ...
... The Dimension Xpand integrated chemistry ... compact footprint to the smaller laboratory. ... the Dimension Xpand integrated chemistry system ... for the low-volume testing environment, in ...
... Dade Behring's Dimension clinical chemistry integrated systems ... Flex reagent cartridge, the power of the ... innovation of the heterogeneous module to meet ... innovation and broad test menus, the systems ...
Medicine Products: